Your NPRA & MDA Gateway

National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia:

The regulatory environment in Malaysia can be complex and time-consuming, which can present challenges in the supply of new drugs and medical devices to the market. Despite these challenges, the future of the Malaysian pharmaceutical industry is bright, poised for continued expansion with strong government commitment to supporting the industry.

Do not let regulatory complexity delay your entry into Malaysia's rapidly expanding pharmaceutical market. Our Malaysia-based regulatory experts, with deep NPRA and MDA knowledge, are ready to accelerate your market access in this MYR6+ billion market projected for significant growth.

to discuss how our Malaysia expertise can position you for success in Southeast Asia's rising pharmaceutical star.

Secured over 20 drug licenses for wide range of product types including NCE, Generics, Biologics/Biosimilars, Drug-Medical Device Combination Products, Supplements, 5 medical device licenses, and 35 cosmetics licenses.

Product Registration Holder as Regulatory and Local Responsible Person in Pharmacovigilance, liaison with National Pharmaceutical Regulatory Agency (NPRA, efficiently handling queries and regulatory communications for Product Registration Holder (PRH) approval.

Handled PRH Transfers, regulatory support for transfer inventory and grace period between Product Owner and Distributor.

Provided comprehensive life cycle management including variations, pharmacovigilance services such as PSUR submission, ICSR, product defect handling, etc.

Provided strategic regulatory intelligence reports, dossier gap analysis to facilitate successful market entry ensuring seamless market entry and compliance.

Malaysia rewards teams that treat NPRA as a partner, not a mailbox. We coordinate pre-submission technical meetings, drive PIC/S GMP inspection applications for overseas sites, and hold the Product Registration Holder role as a locally incorporated SSM company with a permanent address and active QUEST 3+ access.

When we are not the product owner, written authorization still places quality, safety, and efficacy accountability firmly with the PRH—exactly where NPRA expects it.

Our Malaysian entity, QUEST membership, and local liaison are ready for registration and full lifecycle management—so you do not wait on incorporation before the scientific work can start.

Prescription, OTC, or traditional medicine—classification sets the bar. Foreign manufacturers appoint a local authorized representative, file through NPRA’s electronic platform, and present formulation, process, stability, clinical, and labelling evidence that can survive evaluation.

Our team documents assumptions, authority expectations, and decision points so sponsors can approve the plan with clear risk ownership.

Local pharmacists and regulatory specialists stay accountable through query cycles, inspection readiness, and post-approval obligations.

We align labeling, Module 1 localization, and partner communications so commercial launch can follow approval without rework.

Where pathways differ by product class, we sequence filings to protect the critical path and avoid avoidable deficiency letters.

Engagements can scale from a single dossier workstream to a multi-country virtual regulatory function.

PECAN.Solutions scopes each workstream with milestones, document owners, and authority touchpoints so registration, license holding, and commercial access stay on one plan.

Our team documents assumptions, authority expectations, and decision points so sponsors can approve the plan with clear risk ownership.

Local pharmacists and regulatory specialists stay accountable through query cycles, inspection readiness, and post-approval obligations.